John F. Deeken
- Oncology top 2%
- Drug Transport and Resistance Mechanisms 12
- Colorectal Cancer Treatments and Studies 12
- Cancer Treatment and Pharmacology 10
- HER2/EGFR in Cancer Research 9
- Otorhinolaryngology top 2%
- Head and Neck Cancer Studies 10
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 10
- Pharmacology top 5%
- Cancer Research top 10%
-
- HIV/AIDS drug development and treatment 9
-
- Lung Cancer Treatments and Mutations 9
- Co-authors
- Wolfgang LöscherSusan E. BatesRobert W. RobeyOrsolya PolgárKenneth K.W. ToPatricia ManganJane InghamKathryn L. Taylor
- Cited by
- OncologyOtorhinolaryngologyGenetics
- Journals
- Nature Genetics (1 paper)Journal of Clinical Oncology (21 papers)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- United StatesGermanySouth Korea
In The Last Decade
John F. Deeken
87 papers receiving 2.9k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 1.3k
- Otorhinolaryngology 191
- Genetics 292
- Pharmacology 155
- Cancer Research 266
Countries citing papers authored by John F. Deeken
This map shows the geographic impact of John F. Deeken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. Deeken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. Deeken more than expected).
Fields of papers citing papers by John F. Deeken
This network shows the impact of papers produced by John F. Deeken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. Deeken. The network helps show where John F. Deeken may publish in the future.
Co-authorship network
The 25 scholars most cited alongside John F. Deeken, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2021 | 10 | |
| 3 | 2021 | 12 | |
| 4 | 2019 | 2 | |
| 5 | 2019 | 17 | |
| 6 | 2019 | 1 | |
| 7 | 2018 | 46 | |
| 8 | 2018 | 4 | |
| 9 | 2017 | 1 | |
| 10 | 2016 | 2 | |
| 11 | 2013 | 14 | |
| 12 | 2012 | 60 | |
| 13 | 2010 | 80 | |
| 14 | 2009 | 39 | |
| 15 | 2009 | 58 | |
| 16 | 2009 | 22 | |
| 17 | ABCB1 genetic variation influences the toxicity and clinical outcome of patients treated with docetaxel | 2008 | 1 |
| 18 | ABCG2 expression, function and a SNP variant in the NCI drug screen cell lines | 2006 | 1 |
| 19 | 2005 | 3 | |
| 20 | 2004 | 80 |
About John F. Deeken
John F. Deeken is a scholar working on Otorhinolaryngology, Oncology and Genetics, having authored 92 papers that have together received 3.0k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (12 papers), Colorectal Cancer Treatments and Studies (12 papers), Chronic Lymphocytic Leukemia Research (10 papers), Cancer Treatment and Pharmacology (10 papers), Head and Neck Cancer Studies (10 papers), HER2/EGFR in Cancer Research (9 papers), HIV/AIDS drug development and treatment (9 papers) and Lung Cancer Treatments and Mutations (9 papers). The work is most often cited by research in Oncology (1.3k citations), Otorhinolaryngology (191 citations) and Genetics (292 citations). John F. Deeken has collaborated with scholars based in United States, Germany and South Korea. Frequent co-authors include Wolfgang Löscher, Susan E. Bates, Robert W. Robey, Orsolya Polgár, Kenneth K.W. To, Patricia Mangan, Jane Ingham, Kathryn L. Taylor, K. Robin Yabroff and John L. Marshall. Their work appears in journals such as Nature Genetics, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.